Japan· JP-1139001Q1042
エトスクシミド
A ethosuximide product containing エトスクシミド, registered in Japan by ファイザー, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Ethosuximide is registered in 16 of 19 countries.
Countries holding a registration under ATC N03AD01 (ethosuximide), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Ethosuximide · ATC N03AD01
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ethosuximide costs, country by country.
Normalised to the WHO defined daily dose (1.25 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ethosuximide · price per daily dose (1.25 g)
USD · FX 28 Sept 2026
- CH Switzerland$1.83
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- エトスクシミド
- Manufacturer
- ファイザー
- Country
- Japan (JP)
- ATC code
- N03AD01
- ATC class
- Ethosuximide
- Defined daily dose
- 1.25 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
124 interactions on record for ethosuximide.
Graded by severity as the source publishes them — 124 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ethosuximide · interactions on record
124 records
- 124 moderate
Most severe, free to view
- MetoclopramideA03FA01moderate
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
- DronabinolA04AD10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N03AD01
Ethosuximide, as other registers publish it.
- United KingdomEmeside 250mg capsulesFontus Health Ltd
- United KingdomEmeside 250mg/5ml syrupFontus Health Ltd
- United KingdomEpesri 250mg capsulesStrides Pharma UK Ltd
- United KingdomEpesri 250mg/5ml syrupStrides Pharma UK Ltd
- DenmarkEthonorNordic Prime ApS
- DenmarkEthosuximid "2care4"2care4 ApS
- DenmarkEthosuximid "Ebb Medical"Ebb Medical AB
- GermanyEthosuximid GlenmarkGlenmark Arzneimittel Gmbh
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aec129d5-f2f5-421a-b216-680af345d0be GET /v1/drugs/aec129d5-f2f5-421a-b216-680af345d0be?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "5%1mL",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1139001Q1042",
"category": "内用薬",
"price_yen": 7.1,
"generic_name": "エトスクシミド",
"product_name_jp": null,
"therapeutic_class": "1139",
"transitional_expiry": null
}See everything about ethosuximide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.